Synopsis:
Board of Deep Diamond India Limited will meet on 17th October 2025, to approve its strategic entry into AI-based healthcare using facial scan technology and finalise the 45-day rollout plan.
During Wednesday’s trading session, shares of a company engaged in the business of gold and diamond-studded jewellery surged nearly 17 percent on the BSE, after a Board meeting is scheduled to consider the company’s entry into the AI-based healthcare sector.
At 10:26 a.m., the shares of Deep Diamond India Limited were trading in the green at Rs. 6.82 on BSE, up by around 8.3 percent, as against its previous closing price of Rs. 6.3, with a market cap of Rs. 98 crores. The stock has delivered negative returns of over 9 percent in the last one year, but has gained by nearly 59 percent in the last one month.
What’s the News
According to the latest regulatory filings with the BSE, the meeting of the Board of Directors of Deep Diamond India Limited is scheduled to be held on Friday, 17th October 2025, to consider and discuss key strategic matters.
The Board will deliberate and approve the company’s proposed strategic entry into the AI-based healthcare sector, with a focus on leveraging facial scan technology for early detection, diagnostic applications, and wellness solutions. Additionally, the Board will review and approve the implementation roadmap and launch plan for this initiative, which is targeted for rollout within the next 45 days.
Financials & More
Deep Diamond reported a significant growth in its revenue from operations, showing a year-on-year increase of around 1,017 percent from Rs. 0.3 crores in Q2 FY25 to Rs. 3.35 crores in Q2 FY26. Similarly, its net profit increased during the same period from Rs. 0.2 crores to Rs. 2.53 crores, representing an impressive rise of about 1,165 percent YoY.
Deep Diamond India Limited is engaged in the business of rough & polished diamonds, the sale and trading of diamond-studded jewellery & gold jewellery. From FY23, the company has also started the business of providing consultancy services to the Pharmaceutical Industry.
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Stock under ₹10 skyrockets 17% after company likely to foray into AI based healthcare sector appeared first on Trade Brains.